Levetiracetam Tablet
Product Images NDC 69102-105

12 FDA label images from Owp Pharmaceuticals, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 69102-105). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Owp Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Str (Structure)

Str (Structure)
Chemical structure of levetiracetam, showing a pyrrolidone ring with an ethyl group and amide substitution, representative of the active ingredient in Levetiracetam tablets by OWP Pharmaceuticals, Inc.*
FDA Label Image

Fig1 (Figure 1)

Fig1 (Figure 1)
A bar chart comparing the percentage of patients across three groups: Placebo (7.4%, N=95), Levetiracetam 1,000 mg/day (37.1%, N=97), and Levetiracetam 3,000 mg/day (39.6%, N=101). The y-axis represents the percentage of patients, ranging from 0% to 45%. The chart indicates higher percentages for Levetiracetam groups compared to placebo.*
FDA Label Image

Fig2 (Figure 2)

Fig2 (Figure 2)
A vertical bar chart comparing the percentage of patients for three groups: Placebo (6.3%, N=111), Levetiracetam 1,000 mg/day (20.8%, N=106), and Levetiracetam 2,000 mg/day (35.2%, N=105). Each bar shows the proportion of patients with an asterisk above the Levetiracetam groups' percentages.*
FDA Label Image

Fig3 (Figure 3)

Fig3 (Figure 3)
A bar chart comparing the percentage of patients between two groups: Placebo (N=104) and Levetiracetam 3,000 mg/day (N=180). The chart shows approximately 14.4% of patients in the placebo group and 39.4% in the Levetiracetam group for the measured outcome.*
FDA Label Image

Fig4 (Figure 4)

Fig4 (Figure 4)
Bar chart comparing the percentage of patients between placebo and Levetiracetam groups. The placebo group (N=97) shows 19.6% of patients, while the Levetiracetam group (N=101) shows 44.6%, with a marked statistical significance indicated by an asterisk.*
FDA Label Image

Fig5 (Figure 5)

Fig5 (Figure 5)
Bar chart comparing the percentage of patients for placebo (N=51) and Levetiracetam (N=58). The placebo group shows 19.6%, while the Levetiracetam group shows 43.1%. The y-axis represents the percentage of patients, ranging from 0% to 45%.*
FDA Label Image

Fig6 (Figure 6)

Fig6 (Figure 6)
A bar chart comparing the percentage of patients between placebo and Levetiracetam groups. The placebo group (N=84) shows about 45.2% of patients, while the Levetiracetam group (N=79) shows about 72.2%, indicating a higher percentage in the Levetiracetam group.*
FDA Label Image
FDA Label Image

250mg (250mg)

250mg (250mg)
Label for Roweepra (levetiracetam) tablets USP, 250 mg strength. The package contains 120 oral tablets. It includes caution to verify product dispensed and advises dispensing the accompanying medication guide to each patient. Manufactured for OWP Pharmaceuticals, Inc., with manufacturing by Torrent Pharmaceuticals LTD in India. The label shows barcodes and storage instructions.*
FDA Label Image

500mg (500mg)

500mg (500mg)
The packaging label is for Roweepra (levetiracetam tablets USP) 500 mg oral tablets. The label indicates a count of 120 tablets and includes caution and dispensing instructions. It shows the labeler as OWP Pharmaceuticals, Inc. and also notes manufacturing by Torrent Pharmaceuticals LTD in India. The label features a barcode and dosage information prominently in yellow.*
FDA Label Image

750mg (750mg)

750mg (750mg)
Roweepra 750 mg (levetiracetam tablets USP) oral tablets packaging label showing a 120-tablet count. Manufactured for OWP Pharmaceuticals, Inc., with noted caution and dispensing instructions. The label includes the NDC number 69102-106-01 and mentions the manufacturer Torrent Pharmaceuticals LTD.*
FDA Label Image

1000mg (1000mg)

1000mg (1000mg)
Roweepra 1000 mg levetiracetam tablets USP, oral tablet dosage form, packaged as 120 tablets. The label shows the brand name Roweepra, active ingredient levetiracetam, and strength 1000 mg. The labeler is OWP Pharmaceuticals, Inc., with manufacturing by Torrent Pharmaceuticals Ltd. The label includes cautionary text to verify product dispensing and to dispense accompanying medication guides.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.